Dr. Lai-Xi Wang
Dr. Wang is the founder and President of GlycoT Therapeutics LLC. He is a world renowned organic chemist and biochemist with more than 20 years of research experience in carbohydrate chemistry, enzymology, glycobiology, and immunology. He is the inventor of the core chemoenzymatic protein glycosylation technologies enabling the synthesis and glycan remodeling of glycoproteins and therapeutic antibodies. Dr. Wang has the expertise, leadership, and motivation necessary to successfully guide GlycoT to fulfill its mission. Currently Dr. Wang is a tenured full professor in Department of Chemistry and Biochemistry, University of Maryland at College Park. He has published over 150 peer-reviewed papers, most of them are related to chemoenzymatic synthesis, glycoengineering of therapeutic antibodies, and glyco-immunology.
Dr. Qiang Yang
Dr. Yang is the Founding Partner and Director of Research of GlycoT. He is a well-trained biochemist with in-depth experience in chemoenzymatic glycoengineering. In addition, he has intensive experience of drug development in small company setting. Serving as the Lead Scientist (scientific leader) for three years in a startup company (American Gene Technologies, 2010-2013), he successfully led the researches of two pre-clinical therapeutic programs and established several key scientific platforms for the company. With the combination of both outstanding industrial experience and extraordinary expertise in glycoengineering, Dr. Yang will lead the technology and product development in GlycoT.